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Pharmaceuticals and Biopiracy: How the
America Invents Act May Reduce the
Misappropriation of Traditional Medicine
Ryan Levy* and Spencer Green **
For decades, Eastern traditional medicine has been
misappropriated by others who claim it as their own and attempt
to obtain patent protection for it. As long this practice has
existed, the international community has pushed back against it.
Several countries and international bodies have created
databases of traditional knowledge, hoping to preclude the
issuance of patents on that knowledge. Other countries, like
Thailand, have extended intellectual property protection to the
traditional knowledge stakeholders themselves. However, a
recent change to U.S. patent law may have the unintended
consequence of helping resolve the issue of biopiracy.
Prior to the passage of the America Invents Act, a foreign
invention could only serve as prior art to U.S. patents if the
foreign invention itself was patented or if it was described in a
printed publication. Because much traditional knowledge was
never recorded, U.S. law did not consider it to be prior art. This
allowed corporations to obtain patent protection for traditional
medicine, even though indigenous peoples had been using it for
centuries.
The America Invents Act, however, eliminated the requirement
that a public use occur “in this country” to constitute prior art.
As a result, public use of traditional knowledge anywhere in the
world renders it prior art to all subsequent U.S. patent
applications. This article analyzes how this dramatic shift in the
*
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I. INTRODUCTION
In 1995, two Indian immigrants at the University of Mississippi
Medical Center obtained a U.S. patent entitled “Use of turmeric in
wound healing” (the “Tumeric Patent”).1 The patent acknowledged that
turmeric had been used “in India as a traditional medicine for the
treatment of various sprains and inflammatory conditions.” 2 However,
this patent purported to put turmeric to a new use based on “experimental

1

U.S. Patent No. 5,401,504 col. 1 l. 37-39 (filed Dec. 28, 1993); see also Prithwiraj
Choudhury & Tarun Khanna, Bio-Piracy or Prospering Together? Fuzzy Set and
Qualitative Analysis of Herbal Patenting by Firms 24 (Harvard Bus. Sch., Working Paper
14-081, 2014) [hereinafter Choudhury & Khanna, Bio-Piracy], available at http://www.
hbs.edu/faculty/Publication%20Files/14-081_6cfa4f81-d5cb-44f6-9a0c-1fe7c91f61ef.
pdf.
2
‘504 Patent., supra note 1 col. 1 l. 37-39 (filed Dec. 28, 1993).
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evidence.” 3 The inventors claimed a “method of promoting healing of a
wound in a patient, which consists essentially of administering a woundhealing agent consisting of an effective amount of turmeric powder to
said patient.” 4 The problem is that turmeric had, in fact, been used in
wound healing for millennia. 5
Because of the widespread use of turmeric for wound healing,
particularly in India, this patent had the potential to have significant
effects. Indians living in America could infringe the patent by using this
home remedy and Indian companies would be subject to liability if they
exported goods to the United States that used the remedy. 6 In response,
the Indian Council of Scientific and Industrial Research (CSIR) sought
reexamination of the patent. 7 It demonstrated, through ancient Sanskrit
texts and academic publications, that the patented method lacked
novelty. 8 The United States Patent and Trademark Office (USPTO)
issued a Reexamination Certificate in 1998 cancelling every claim of the
patent. 9 Thus, with respect to the Turmeric Patent, the patent system
corrected itself. A bad patent was issued on traditional medicine, adverse
parties utilized the available administrative procedures, and the USPTO
cancelled the claims.
However, due to geographic limitations on prior art, patents based on
or claiming traditional knowledge are not always invalidated. Many
traditional knowledge stakeholders do not have the benefit of printed
publications embodying their knowledge. Under pre-America Invents
Act (AIA) law, patents on that knowledge remain valid. 10 Moreover, the
mere grant of a patent on a method for using turmeric in wound healing
brought about significant social harm, despite its later invalidation. A
remedy that the Indian people had utilized for thousands of years was
now owned by the University of Mississippi Medical Center.11 The
Indian people were outraged that a patent had been granted on
3

Id.
Id. col. 3 l. 4-7.
5
Choudhury & Khanna, Bio-Piracy, supra note 1, at 23.
6
See 35 U.S.C. § 271(a) (2012) (providing that “whoever without authority makes,
uses, offers to sell, or sells any patented invention, within the United States or imports
into the United States any patented invention during the term of the patent therefor,
infringes the patent.”).
7
TOBIAS KIENE, THE LEGAL PROTECTION OF TRADITIONAL KNOWLEDGE IN THE
PHARMACEUTICAL FIELD 17 (2011).
8
Id; ‘504 Patent., supra note 1 Reexamination Certificate (issued Apr. 21, 1998).
9
Id.
10
Patents issued before March 18, 2013 are governed by the Patent Act, rather than by
the America Invents Act. Medisim Ltd. v. BestMed, LLC, 758 F.3d 1352, 1354 n.1 (Fed.
Cir. 2014). Under the Patent Act, foreign inventions were not regarded as prior art unless
they were “patented or described in a printed publication.” 35 U.S.C. § 102(a) (2006).
11
Choudhury & Khanna, Bio-Piracy, supra note 1, at 23.
4
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“something that has been the collective wisdom of a people for
centuries.” 12
The USPTO has received tens of thousands of patent applications
relating to traditional uses of Indian and Chinese herbal remedies.13
However, a recent change in U.S. patent law will affect whether such
patents continue to be granted, whether they are enforced, and how the
patent claims are drafted. Prior to the passage of the America Invents Act
(AIA), 14 foreign public use, sale, or knowledge of these traditional
remedies was not regarded as “prior art” to U.S. patents.15 As a result,
even if traditional remedies had been used for thousands of years outside
the United States, they could not be used to invalidate a U.S. patent
unless they were published. 16 The AIA changed that by eliminating the
“in this country” limitation to those types of prior art.17
This article addresses how the America Invents Act will affect the
patent strategies of pharmaceutical companies seeking U.S. patents based
on traditional medicine. It also discusses whether the AIA has created a
new avenue through which traditional knowledge stakeholders may
invalidate patents based on traditional medicine. Part I provides
background on the history of geographic limitations to prior art under
U.S. patent law. Part II discusses biopiracy, how it affects traditional
knowledge stakeholders, and how Western firms have responded to
charges that they expropriated traditional knowledge. Part III discusses
the various measures that governmental entities and international bodies
have taken in order to combat biopiracy. Part IV identifies and discusses
the particular changes to the U.S. patent system under the AIA that may
affect pharmaceutical companies’ ability to obtain protection for
inventions based on traditional knowledge.

12

Id. at 26.
Prithwiraj Choudhury & Tarun Khanna, Codifying Prior Art and Patenting: Natural
Experiment of Herbal Patent Prior Art Adoption at the EPO and USPTO 15 (Harvard
Bus. Sch., Working Paper No, 14-079, 2014) [hereinafter Choudhury & Khanna, Prior
Art], available at http://www.hbs.edu/faculty/Publication%20Files/14-079_9f881e56002c-4603-a778-5a698184c827.pdf.
14
Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011)
(codified at 35 U.S.C. §§ 1–390 (2011)) [hereinafter America Invents Act or AIA].
15
35 U.S.C. § 102(a) (2006).
16
Id.
17
See 35 U.S.C. § 102(a) (2012).
13
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A BRIEF HISTORY OF GEOGRAPHIC LIMITATIONS ON PRIOR
ART

Geographic limitations on prior art have been a long-standing feature
of U.S. patent law following passage of the Patent Act of 1836. 18 Before
the advent of airplanes and the Internet, which carry products and
information rapidly across the world, geographic limitations on prior art
enabled American “inventors”—who sought to commercially exploit
foreign inventions in this country—to receive patents on that technology,
despite not having invented it. 19 Nonetheless, these patents were
arguably consistent with the Constitution’s Intellectual Property Clause,
which grants Congress the power “to promote the progress of science
and the useful arts.” 20 These entrepreneurs introduced to the United
States new technology that would otherwise be unavailable, thereby
promoting the progress of science in this country. 21 In the modern world,
however, geographic limitations on prior art are no longer required to
ensure that new technology is made available across seas. Advances in
how people trade information globally also reduce the burden of
examining patent applications in light of all prior art, wherever it may be
found.
The U.S. patent system seeks to do more than simply encourage the
introduction of new products into American markets. There are costs
associated with granting monopolies to patent holders and removing
information from the public domain. To properly balance those costs
against the social and economic benefits of the introduction of new
technology, the Framers understood the Intellectual Property Clause to
embody certain limitations. Patents may not be granted to non-inventors,
and inventions in the public domain may not be removed from the public
domain. 22 Modern patent law reflects those understandings by granting
patent protection only to inventors who have “invent[ed] or
discover[ed]” technologies 23 that are useful, 24 novel, 25 non-obvious, 26
18
Patent Act of 1836, ch. 357, 5 Stat. 117, Sec. 7 (1836). (providing that a patent shall
only issue if the invention “had [not] been invented or discovered by any other person in
this country prior to the alleged invention or discovery thereof by the applicant . . . or
described in any printed publication in this or any foreign country.”).
19
If, however, each of the claim limitations was embodied in a printed publication, a
U.S. patent would be denied. See id.
20
U.S. CONST. art I, § 8, cl. 8.
21
See Margo A. Bagley, Patently Unconstitutional, 87 MINN. L. REV. 679, 684 (2003)
(arguing that geographic limitations on prior art are unconstitutional because they permit
the patenting of inventions in the public domain).
22
Id.
23
35 U.S.C. § 101 (2012).
24
Id.
25
35 U.S.C. § 102 (2012).
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and enabled. 27 By eliminating geographic restrictions on prior art, the
America Invents Act has broadened the scope of prior art in a way that
may prevent future patents on traditional knowledge. In doing so, it will
help ensure that the U.S. patent system does not prejudice the public or
harm traditional knowledge stakeholders.

III.

THE PROBLEM OF BIOPIRACY

“Biopiracy” describes circumstances in which “developed countries
use biotechnology patents to expropriate the biological [or] genetic
heritage of less developed countries.” 28 Accusations of biopiracy
typically involve the theft of traditional knowledge that is otherwise held
by indigenous people. 29 The textbook example involves valuable uses of
local plants or animals within a particular indigenous community.
Corporations may become aware of these uses, then seek to patent and
commercialize that knowledge for their own gain.30 Companies often
attempt to patent rights in indigenous knowledge or the products and
methods derived from that knowledge. 31 As such, the patentee may
receive significant financial compensation for their patent rights, while
leaving the indigenous community with no gain.

A.

Biopiracy in the Pharmaceutical Industry

Due to the medicinal nature of much traditional knowledge,
pharmaceutical companies are among the most common perpetrators of
biopiracy. Consumers often have allergies to drugs or simply desire to
avoid the side effects associated with such medicines. 32 As a result, the
market for pharmaceutical products based on traditional knowledge is
growing, and pharmaceutical companies seek to take advantage. 33 These
companies frequently become aware of traditional remedies for common
medical problems, then commercialize and patent some variation of
26

35 U.S.C. § 103 (2012).
35 U.S.C. § 112 (2012).
28
Baruch A. Brody, Traditional Knowledge and Intellectual Property, 20 KENNEDY
INST. OF ETHICS J. 231 (2010).
29
Id.
30
Id. at 232.
31
Peter Drahos, Indigenous Knowledge, Intellectual Property and Biopiracy, 22 EUR.
INTELL. PROP. REV. 245 (2000).
32
J. Maheswari, Patenting Indian Medicinal Plants and Products, 4 INDIAN J. SCIENCE
& TECH. 298, 300 (2011).
33
See Chika A. Ezeanya, Contending Issues of Intellectual Property Rights Protection
and Indigenous Knowledge of Pharmacology in Africa South of the Sahara, 6 J. PAN AFR.
STUD. 24, 29 (2013).
27
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those remedies for their own benefit. The USPTO receives literally
thousands of patent applications that relate in some way to traditional
knowledge. 34
Below are a few of the most well-known instances of pharmaceutical
biopiracy. These examples reflect the complexity of the issues, the
varying cultural perceptions on the commercialization of traditional
medicine, and the limits of the patent system’s ability to resolve these
conflicts.

i. Kwao krua
The Thai herb kwao krua had been used for over 100 years and its
medicinal uses had been documented in Thai writings as early as 1931. 35
More recently, however, certain plant-produced hormones have been
discovered in the plant.36 These hormones have been used in modern
medicine to enhance male sexual performance, enlarge and firm breasts,
and firm the skin. 37 A company based in South Korea holds a U.S. patent
on an extract from kwao krua for some of these purposes. 38
The concern for the Thai people is that the steps for extraction
disclosed in the patent do not differ from the methods that practitioners
of traditional medicine have used for nearly a century. 39 Unfortunately,
publications discussing this practice were not considered as prior art to
the U.S. patent. 40 Threats of legal action have disrupted local producers
of kwao krua and the plant has been harvested quickly for commercial
purposes, which does not allow time for the plant’s regrowth.41 Due to
the grant of intellectual property protection in this traditionally used plant
and its extract, indigenous peoples’ customs relating to the plant’s
ordinary production and use have been disturbed.42

ii. Hoodia
The San people of the Kalahari Desert in South Africa have been
using Hoodia, a local plant, as an appetite-suppressant since ancient

34

Choudhury & Khanna, Prior Art, supra note 1, at 15.
DANIEL F. ROBINSON, CONFRONTING BIOPIRACY: CHALLENGES, CASES
INTERNATIONAL DEBATES 55 (2010).
36
Id.
37
Id.
38
U.S. Patent No. 6,673,377 (filed Aug. 28, 2000).
39
ROBINSON, supra note 35, at 55.
40
See id.
41
Id. at 59.
42
See id.
35
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times. 43 Suppressing their appetite by consuming Hoodia allowed them
to engage in longer hunting expeditions and carry fewer supplies,
increasing the productivity of the hunts.44 Pursuant to an international
treaty, the Convention on Biodiversity (CBD), the San people have
received royalty payments for the sales of drugs containing Hoodia by
multinational pharmaceutical companies.45 However, serious questions
remain about the fairness and propriety of such profit-sharing
agreements. 46 Moreover, the United States is not a party to the CBD, so
profits gained through the exploitation of the U.S. patents on Hoodia
result in no benefit to the San people.47 Thus, numerous patents that
incorporate the San people’s indigenous knowledge of Hoodia have been
granted in both the United States and Europe, with little or no benefit
from the sales of products protected by those patents to the San people.

iii. Madagascar rosy periwinkle
The commercialization of the healing properties of the Madagascar
rosy periwinkle is another example of a pharmaceutical company reaping
the rewards of Eastern medicinal plants. The plant had been long used in
traditional medicine by the indigenous communities of Madagascar,
among others. 48 Inspired by the use of this plant in traditional medicine,
Eli Lilly & Company 49 isolated two extracts that give the plant its
healing properties: vinblastine and vincristine. 50 Those extracts are now
used in drugs the company markets for the treatment of cancer.51 Eli Lily
receives around $100 million each year from these drugs, but the
indigenous peoples of Madagascar do not share in the profits. 52

43
Fritz Dolder, Traditional Knowledge and Patenting: The Experience of the
Neemfungicide and the Hoodia Cases, 26 BIOTECHNOLOGY L. REP. 583, 587 (2007).
44
Id.
45
Saskia Vermeylen, Contextualizing ‘Fair’ and ‘Equitable’: The San’s Reflections on
the Hoodia Benefit-Sharing Agreement, 12 LOC. ENV’T 423, 428 (2007).
46
See generally id. (discussing the San people’s perceptions of the fairness of the
Hoodia Benefit Sharing Agreement); see infra Part I.C.
47
List
of
Parties,
CONVENTION
ON
BIOLOGICAL
DIVERSITY,
http://www.cbd.int/information/parties.shtml (last visited Mar. 29, 2015) (listing the
parties to the CBD).
48
Michael Hassemer, Genetic Resources, in INDIGENOUS HERITAGE AND
INTELLECTUAL PROPERTY, 151, 168 (ed. Silke von Lewinski 2004).
49
Eli Lilly & Company has approximately 39,000 employees worldwide, markets
products in 125 countries, and had net sales of over $23 billion in 2013. Key Facts, ELI
LILLY & CO., http://www.lilly.com/about/key-facts/Pages/key-facts.aspx (last visited
Mar. 29, 2015).
50
Hassemer, supra note 48 at 168.
51
Id.
52
Id.
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Despite the perceived misappropriation of Malagasy culture,
Malagasy healers never used the rosy periwinkle for the uses to which
Eli Lilly is putting it. They used it primarily in treating diabetes.53
Because Eli Lilly used the plant to produce new compounds, for new
medicinal uses, they may be able to obtain patent protection even under
the America Invents Act. 54 However, the expanded scope of prior art
under the new Section 102 will not be without impact on Eli Lilly’s
ability to patent these sorts of inventions. Consideration of the Malagasy
use may force companies like Eli Lilly to narrow their patent claims,
directing them only at the new innovation. Accordingly, even where
prior art may not entirely bar new patents, its consideration may affect
the reach of new patent claims.

B.

Negative Consequences of Biopiracy

The greatest criticism of the expropriation of indigenous medical
knowledge by for-profit companies is that it is simply unfair. 55 These
critics argue that pharmaceutical companies are permitted to realize
millions of dollars in sales from some traditional remedies with little or
no payment to the actual indigenous knowledge holders.56 Critics of the
Turmeric Patent leaned heavily on the perceived unfairness of patenting
a remedy that had been used to heal wounds in India for hundreds of
years. 57 It was also an issue in Eli Lilly’s use of the Madagascar rosy
periwinkle, which generates $100 million in sales for the company
annually. 58 Ironically, the patenting of traditional knowledge may cause
the sale of products embodying traditional knowledge to the traditional
knowledge holders at monopoly prices. 59 Such sales, however, would

53

Id.
The AIA would consider medicinal uses of the plant that were known to the public
to be prior art. 35 U.S.C. § 102 (2012).
55
See e.g., Lester I. Yano, Protection of the Ethnobiological Knowledge of Indigenous
Peoples, 41 UCLA L. REV. 443, 445 (arguing that permitting drug developers to profit off
indigenous knowledge without compensating indigenous practitioners “is unfair and
hypocritical.”); David Conforto, J. ENVTL. L. & LITIG. 357, 365 (acknowledging the
perceived unfairness of geographic restrictions on prior art). But see generally Jim Chen,
37 MCGEORGE L. REV. 1 (arguing that biopiracy is only a perceived problem, not an
actual problem, and that the “biopiracy narrative” is false).
56
See e.g., Yano, supra note 55.
57
See Choudhury & Khanna, Bio-Piracy, supra note 1, at 25-26.
58
Hassemer, supra note 48, at 168.
59
Martin Khor, IPRs, Biodiversity, and the Theft of Indigenous Knowledge, 28
INTERDISC. SCI. REVIEWS 7, 8 (2003).
54
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have to occur within the United States to obtain the benefit of the
monopoly a U.S. patent would provide. 60
The most egregious examples of the exploitation of traditional
knowledge can occur when individuals and companies are prevented
from utilizing knowledge that they had been using for centuries. An
American patent does not preclude exportation of the patented invention
to foreign countries, but it does prevent importation of products
embodying the claimed invention to the U.S. 61 Due to the threat of legal
action, many such entities in countries that serve as the source of
traditional knowledge have been precluded from using that knowledge. 62
For instance, despite a history of the use of kwao krua by the indigenous
people of Thailand, threats of legal action have disrupted local
production of the herb. 63
In India, individuals and companies had been using extract from
neem trees for centuries to repel insects and bacterial diseases. 64 Once a
patent on a variation of this extract was granted to W.R. Grace & Co., the
company sought to force Indian companies producing neem-based
products to license its technology. 65 Local companies feared that this
patent would preclude them from exporting goods to the U.S. market and
would drive up the price of neem seeds.66 By depriving Indian companies
of their ability to export certain neem-based products to the world’s
largest economy, the neem patent deprived Indian people of their ability
to exploit their indigenous knowledge within the world economy. 67 This
led to a worldwide campaign to cancel the patent.68 By allowing for
patent protection on inventions derived from traditional knowledge, the
60

See 35 U.S.C. § 271(a) (2012) (limiting patent infringement to infringements
“within the United States” or importation “into the United States.”)
61
Id.
62
This use preclusion extends to personal uses only to the extent that patented methods
are being used inside the United States. The primary impact is with respect to
commercialization of traditional knowledge because products embodying the patents
would be shipped to the U.S.
63
ROBINSON, supra note 35, at 59.
64
Itsuki Shimbo et al., Patent Protection and Access to Genetic Resources, 26 NATURE
BIOTECHNOLOGY 645, 645 (2008).
65
Id.
66
Shayana Kadidal, Subject-Matter Imperialism? Biodiversity, Foreign Prior Art and
the Neem Patent Controversy, 37 IDEA 371, 376-77 (1997). But see Emily Marden, The
Neem Tree Patent: International Conflict Over the Commodification of Life, 22 B.C.
INT’L & COMP. L. REV. 279, 285 (articulating that effects of the neem patent on Indian
farmers are unclear and that the patent may help Indian farmers because W.R. Grace
processes its seeds in India).
67
Jonathan B. Warner, Using Global Themes to Reframe the Bioprospecting Debate,
13 IND. J. GLOBAL LEGAL STUD. 645, 651–652 (2006).
68
Shimbo, supra note 64.
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use of the traditional knowledge itself amongst indigenous people may
be eroded. 69
Not only is the patenting of these traditional remedies unfair to the
indigenous knowledge holders, it is also unfair to the public, who grants
the “inventors” of these remedies the right to exclude others.70 The grant
of patent protection to inventors is based on a quid pro quo with society.
Inventors agree to disclose their discoveries to the public through the
patent’s specification and, in return, the public grants them an exclusive
right to exploit those discoveries for a limited time. In this way, both the
inventor and the public benefit from the protections that patent law
provides. This paradigm breaks down, however, when the discovery to
be disclosed is already known to the public. If the invention has been
used publicly for thousands of years, there is no benefit to the public in
granting the patentee the exclusive right to exploit it. When well-known
traditional knowledge is patented, there can be no quid pro quo, and the
public does not get the benefit of its bargain.

C.

Royalties Paid to Indigenous Knowledge Stakeholders

In response to the backlash that companies face due to their
misappropriation of traditional knowledge and pursuant to the Nagoya
Protocol under the Convention on Biological Diversity (CBD), which
requires benefit-sharing agreements with indigenous people, companies
will occasionally pay royalties to indigenous knowledge stakeholders.
While this scenario is fairer than it would be if no royalties were paid, it
is accompanied by its own unique set of problems. Conceptions of
fairness are culturally defined and indigenous peoples are often
concerned with social, environmental, and spiritual concerns that are not
accounted for by most profit-sharing agreements. 71 Therefore, while the
payment of royalties may be perceived as “fair” by the pharmaceutical
companies that are exploiting traditional knowledge, such arrangements
may not be perceived as fair by the indigenous people themselves. 72
The CBD sought to resolve a fundamental dispute regarding the
ownership of genetic resources by declaring that states’ sovereign rights
over natural resources extend to genetic resources.73 This model requires
a “government-to-government approach,” even though private actors
69

Khor, supra note 59, at 8.
See supra Part I.
71
Vermeylen, supra note 45, at 425-26.
72
See id.
73
Matthias Buck & Claire Hamilton, The Nagoya Protocol on Access to Genetic
Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization
to the Convention on Biological Diversity, 20 REV. EUR. COMMUNITY & INT’L L. 47, 47
(2011).
70
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ordinarily conduct transactions in genetic resources and traditional
knowledge. 74 The CBD has raised the level of protection for sovereign
rights to genetic resources, but has not augmented the level of protection
for the traditional knowledge holders themselves.75 Moreover, because
each member government has interpreted the provisions of the CBD
differently, standards governing the obligations of the parties and the
fairness of benefit-sharing agreements vary dramatically. 76
A prime example of how these benefit-sharing agreements under the
CBD fail to compensate most traditional knowledge holders is in the
treatment of the San people of Southern Africa. 77 The San’s traditional
knowledge relating to consuming Hoodia as an appetite suppressant is
the subject of a benefit-sharing agreement through South Africa’s
Council for Scientific and Industrial Research (CSIR). 78 Through the
benefit sharing agreement, the CSIR has permitted companies such as
Pfizer and Unilever to commercially exploit Hoodia. 79 The San never
granted prior informed consent for the commercialization of their
traditional knowledge. 80 Thus, the San began in a disadvantaged
bargaining position and did not obtain an equitable benefit-sharing
agreement. In fact, the vast majority of San people had never even heard
of the benefit-sharing agreement. 81 Under the benefit-sharing agreement,
the CSIR was to pay the San peoples eight percent of the “milestone
payments” made by licensees during the drug’s clinical development. 82
After the drug’s development was completed, the San would receive a
six percent royalty on the marketing of the drug. 83
To make matters worse, the very existence of a benefit-sharing
agreement disturbed long-standing San values regarding egalitarianism. 84
To facilitate the negotiation of a benefit-sharing agreement, the San were
pressured to elect leaders, thus changing the nature of group-decision
making that had previously prevailed in San culture.85 Most of the San
74

Id. at 48.
Id. at 56.
76
Id. at 55-56.
77
See supra Part II.A.iii.
78
Vermeylen, supra note 45, at 427.
79
World Health Organization, Protecting Traditional Knowledge: the San and Hoodia,
84 BULL. OF THE WHO 345 (2006). See also Ezeanya, supra note 33, at 30 (discussing the
sublicensing of Hoodia to Pfizer).
80
Vermeylen, supra note 45, at 427.
81
Id. at 429.
82
Leon Marshall, Africa’s Bushmen May Get Rich from Diet-Drug Secret, Nat’l
Geographic News (Apr. 16, 2003), available at http://news.nationalgeographic.com/
news/2003/04/0416_030416_san1.html.
83
Id.
84
Vermeylen, supra note 45, at 431.
85
Id.
75
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people were not consulted regarding the benefit-sharing agreement and
cared less about monetary compensation than they did about nonmonetary benefits, such as access to education and land.86 They also
expressed concerns that the money would be wasted and misused by
public officials.87 These people’s interests were not represented. Not only
did the majority of the San people not gain any tangible benefit from the
benefit-sharing agreement, the benefits that were gained came at the
expense of their traditional mode of decision-making.

IV.

PUSHBACK FROM THE INTERNATIONAL COMMUNITY

Unsurprisingly, the perceived unfairness of allowing companies to
expropriate traditional knowledge for their own commercial gain has
been met with strong international resistance. Countries with vast
traditional knowledge have sought to protect that knowledge either by
publishing it in English or by granting property rights in that knowledge
to the indigenous people. Additionally, international treaties, such as the
CBD, have sought to address the problem by providing some protections
for indigenous knowledge stakeholders. This Part explores the two major
ways that countries rich in traditional knowledge seek to prevent the
misappropriation of that traditional knowledge, as well as suggestions
that have been made by the World Intellectual Property Organization
(WIPO).

A.

Traditional knowledge databases

The most obvious and effective means of preventing the grant of
patents based on traditional knowledge is to ensure that the traditional
knowledge will be considered as prior art. At the most basic level, if
those opposing the issuance of a patent can demonstrate that the
“invention” is already known to the public, the invention is ineligible for
patent protection either because it is not novel or because the invention’s
improvement over the prior art would have been obvious to person of
ordinary skill in the art.88 One of the reasons that patents based on
traditional knowledge have been granted under U.S. law—despite their
obviousness or lack of novelty—is that foreign “public use” did not
qualify as prior art. 89 Foreign prior art must have been published in
English to be considered by the USPTO and federal courts. 90 In response,
86
87
88
89
90

Id. at 430.
Id.
See 35 U.S.C. §§ 102–103 (2012).
35 U.S.C. § 102 (2006).
37 C.F.R. § 3.26 (2014).
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various governments and international organizations have created
traditional knowledge databases that serve as a published written record
of the traditional knowledge.
The most inclusive of these databases is WIPO’s “Centralized
Access to Search and Examination” (CASE) database. While not
specifically directed at traditional knowledge, CASE facilitates
communication amongst patent offices worldwide.91 This allows patent
examiners to view patent applications in other participating jurisdictions
and share their own examination results.92 For instance, if a patent
application based on medical uses of indigenous Australian plants is filed
in the United Kingdom’s Intellectual Property Office, the UK patent
examiner can access the database to determine whether any similar
applications had been filed with IP Australia. 93 In this way, the scope of
available prior art and the accessibility of that prior art are both
improved.
WIPO’s PATENTSCOPE Search System provides patent attorneys,
inventors, and researchers a free and accessible way to search patent
documents from over thirty participating countries and organizations. 94
In addition to WIPO’s databases, China, India, the Republic of Korea,
Bioversity International, Peru, the Philippines, the Inuit of Nunavik, and
the Dene in Canada have all established databases directed specifically
towards traditional knowledge. 95 These databases consist of English
language documents that have recorded traditional knowledge.
These traditional knowledge databases have had a measurable impact
on the subject matter of patents that have been granted. For instance,
following the EPO’s adoption of India’s traditional knowledge database,
new patents based on herbal formulations were ninety-six percent more
likely to be a mix of herbal and synthetic formulations. 96 This trend is
likely the result of patent applicants seeking to avoid the prior art.
Synthetic formulations are more likely to be novel than herbal ones.
Therefore, if a patent applicant can improve upon traditional herbal
91

WIPO CASE—Centralized Access to Search and Examination, WIPO, http://www.
wipo.int/case/en/ (last visited Mar. 29, 2015).
92
Id.
93
IP Australia is Australia’s administrative body that “administers intellectual property
rights and legislation relating to patents, trademarks, designs and plant breeder’s rights.”
IP AUSTRALIA, About Us, http://www.ipaustralia.gov.au/about-us/ (last updated Mar. 20,
2015).
94
WIPO, PUB. NO. L43/8E, PATENTSCOPE SEARCH: THE USER’S GUIDE 1-2 (2013),
available at http://www.wipo.int/edocs/pubdocs/en/patents/434/wipo_pub_l434_08.pdf.
95
WIPO, PROGRESS REPORT ON THE STATUS OF TRADITIONAL KNOWLEDGE AS PRIOR
ART 33 (2001) [hereinafter WIPO, PROGRESS REPORT], available at http://www.wipo.int/
edocs/mdocs/tk/en/wipo_grtkf_ic_2/wipo_grtkf_ic_2_6.pdf.
96
Choudhury & Khanna, Prior Art, supra note 1, at 30.
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remedies by introducing some synthetic component, that applicant is
more likely to avoid the novelty and non-obviousness issues that are
associated with deriving an invention from traditional knowledge. By
forcing patent applicants to consider a broader range of prior art,
traditional knowledge databases have spurred innovation. Not only do
databases preclude patents based on existing traditional knowledge, they
force inventors to improve upon traditional remedies through additional
innovation.

B.
Sui Generis: Granting property rights in traditional
knowledge
While establishing traditional knowledge databases is focused on
preventing third parties from obtaining intellectual property protection
for traditional knowledge, some countries have affirmatively provided
for intellectual property protection to traditional knowledge stakeholders.
This sort of system, which creates new categories of intellectual property
rights for traditional knowledge, has been characterized as a sui generis
regime. 97 Thailand, for example, has extended intellectual property
protection to traditional Thai medicine through the Act on Protection and
Promotion of Traditional Thai Medicinal Intelligence.98 Under this
statute, the rights holder has the sole right to produce, distribute, or
improve upon the medicine. 99 Anyone seeking to use Thai traditional
medicine for commercial benefits is required to apply to “obtain
benefits” and must pay fees for their use of the traditional medicine.100
While this law will likely deter or prevent some of the types of
misappropriation described in this article, it opens the door to domestic
misappropriation of traditional medicine and alienates the indigenous
people themselves. Indigenous Thai peoples, such as the Karen, hold
views regarding traditional medicines, and the herbs that create them,
that are fundamentally incompatible with intellectual property
protection. 101 The Karen people reject the viewpoint that natural
97

See J. Janewa OseiTutu, A Sui Generis Regime for Traditional Knowledge: The
Cultural Divide in Intellectual Property Law, 15 MARQ. INTELL. PROP. L. REV. 147, 150–
51 (noting that legislatures in countries that possess vast traditional knowledge may seek
to create sui generis rights to protect that traditional knowledge).
98
Act on Promotion and Protection of Traditional Thai Medicinal Intelligence, B.E.
2542 (1999) (Thai.), translation available at http://www.wipo.int/wipolex/en/text.jsp?
file_id=179713.
99
Id. § 34.
100
Id. § 19.
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This article takes no position on whether such views are preferable to well
established patent regimes, such as that in the United States. For more information on the
cultural differences relating to intellectual property protection, see generally OseiTutu
supra note 97.
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resources, such as herbs, should be considered resources at all.102 They
believe that plants and animals have spirits and should be respected like
humans are. 103 Thus, medicines should not be hoarded and should not be
traded for a profit. 104 If medicinal herbs are abused through commercial
exploitation, practitioners of traditional Karen medicine would perceive
this as an abuse of the herbs’ spirit and internalize that harm. 105
Ironically, by refusing to grant patents on such knowledge, the U.S.
patent system may be more consistent with traditional Karen values than
the Thai system. The Act on Protection and Promotion of Traditional
Thai Medicinal Intelligence may enable local practitioners of traditional
medicine to claim a monopoly on the use of certain remedies. The law’s
requirement that users of traditional medicine pay royalties is
inconsistent with the Karen people’s beliefs relating to the use of these
herbs. From the Karen’s perspective, commercialization and the grant of
exclusive rights over the medicinal use of certain herbs would be an
abuse of the herb’s spirit and would cause a spiritual injury to indigenous
medical practitioners themselves. 106 Rather than protecting traditional
knowledge stakeholders, as they purport to do, these types of laws can be
adverse to the interests of indigenous peoples if they do not carefully
consider local religion and customs. By contrast, the AIA would not
allow a patent on this traditional knowledge and consequently would
preserve the spiritual integrity of Karen medicine.

C.
WIPO Progress Report on the Status of Traditional
Knowledge as Prior Art
Although WIPO has not undertaken to attempt to solve the issue of
biopiracy, it has made suggestions to member states that seek to resolve
whether traditional knowledge should qualify as prior art.107 WIPO’s
Progress Report on the Status of Traditional Knowledge as Prior Art
identifies two particular problems in establishing traditional knowledge
as prior art. 108 First, the definition of prior art in many jurisdictions
excludes most traditional knowledge. 109 For example, U.S. patent law
effectively excluded most traditional knowledge as prior art before the
102

Daniel F. Robinson, Legal Geographies of Intellectual Property, ‘Traditional’
Knowledge and Biodiversity: Experiencing Conventions, Laws, Customary Law, and
Karma in Thailand, 51 GEOGRAPHICAL RES. 375, 379 (2013).
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enactment of the America Invents Act. 110 Second, on a practical level,
traditional knowledge may be difficult for patent examiners to
discover. 111 Traditional knowledge, even when it is recorded in databases
or other writings, is often not arranged in an orderly manner. 112 It is
difficult to search, which diminishes its value to patent examiners
looking for prior art.
To address these issues, WIPO suggests that IP offices and
traditional knowledge documentation initiatives “build bridges” to enable
more effective communication.113 To facilitate this bridge-building,
WIPO suggests that member nations begin by establishing more efficient
classification systems. 114 While the International Patent Classification
(IPC) system is extremely effective and is used on ninety-five percent of
all patent documents, a more detailed system is needed for traditional
medicine. 115 One such example is India’s Traditional Knowledge
Resource Classification (TKRC) system. 116 A more detailed and
organized system for arranging traditional knowledge would allow
people to find the relevant prior art that they are looking for.

V.

CHANGES IN THE SCOPE OF “PRIOR ART”

Some of the most widely debated reforms under the America Invents
Act are contained in the new Section 102. One of the primary goals of
the America Invents Act was to bring the U.S. patent system in line with
the rest of the world.117 Section 102 served as one of the primary vehicles
for accomplishing that goal, in part, by eliminating geographic
restrictions on public use, sale, or knowledge as prior art.118 This
dramatic shift in the scope of prior art to the U.S. patent system is likely
to have unforeseen consequences in the context of biopiracy and the
protection of traditional knowledge. Public knowledge, sale, or use of
traditional knowledge outside the United States may now serve as prior
110

See supra Part II.
WIPO, PROGRESS REPORT, supra note 95, at 14.
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European Patent Convention, 12 WASH. U. GLOBAL STUD. L. REV. 807, 807 (2013).
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The new Section 102 made other major changes to the U.S. patent system to bring it
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art to U.S. patents. Thus, applicants seeking U.S. patent protection based
in part upon traditional knowledge may have more difficulty prosecuting
and maintaining patents due to the changes to Section 102, which
effectively renders most traditional knowledge ineligible for patent
protection in the United States.

A.
Substantive changes to U.S. patent law under the America
Invents Act
Under the 1952 Patent Act, a person could not obtain a patent if “the
invention was known or used by others in this country, or patented or
described in a printed publication in this or a foreign country, before the
invention thereof by the applicant for a patent.” 119 By the plain language
of the statute, the only foreign art that could serve as a bar to a U.S.
patent were patents and printed publications. U.S. courts applied this
requirement strictly, rejecting challenges to the novelty or nonobviousness of U.S. patents based on a foreign public use of the
invention. 120 In the context of biopiracy, this rule presented a significant
challenge to those attempting to protect the interests of traditional
knowledge stakeholders. Traditional knowledge is rarely published, so it
rarely served as prior art to U.S. patents.
The disputes surrounding the patentability of compounds derived
from the neem tree embodied this very problem. In the early 1990s,
American researchers found a way to improve upon a traditional Indian
pesticide derived from the neem tree by making it suitable for long-term
storage. 121 Although this improvement, arguably, would have been
obvious to Indian farmers, under Section 102 foreign knowledge could
only serve as a bar to a U.S. patent if it was published prior to the
“invention” by the U.S. applicant. 122 In 1995, a coalition of 225 groups
and over 100,000 individual farmers filed a petition with the USPTO
seeking to invalidate the patent.123 Although a similar patent 124 was
invalidated by the European Patent Office (EPO),125 the U.S. patent
119

35 U.S.C. § 102(a) (2006).
See, e.g., E. I. du Pont de Nemours & Co. v. Berkley & Co., 620 F.2d 1247, 1265
(8th Cir. 1980) (holding that evidence of an invention’s use in France was inadmissible to
show the obviousness of an American patent).
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remains valid because pre-AIA law continues to apply to patents granted
before the AIA took effect.126 These differing results are likely explained
by the difference between the EPO, which is permitted to consider
foreign knowledge, and the old Section 102, which excluded such
knowledge if it was not published.
Since the passage of the America Invents Act, however, the scope of
prior art under the U.S. patent system has been brought in line with the
European system. The new Section 102 removed the “in this country”
limitation that used to apply to the “public use” and “on sale” bars. It
also added the phrase “available to the public” to “clarify the broad scope
of relevant prior art.” 127 U.S. law no longer requires publication for
foreign prior art to block a U.S. patent. Prior art for patents issued under
the American Invents Act “will no longer have any geographic
limitations.” 128
The changes to Section 102 also included the addition of “or
otherwise available to the public” as a broad category of prior art. While
Congress indicated that the purpose of the phrase “available to the
public” was “to clarify the broad scope of relevant prior art, as well as to
emphasize the fact that it must be publically available,” there was no
guidance as to what type of prior art was covered by this phrase and not
the remainder of Section 102(a)(1).129 One interesting postulation as to
the different prior art covered by “or otherwise available to the public” is
that the clause could include orally transmitted information that had yet
to be physically recorded. 130 Though appearing inadvertent, this change
to Section 102 by the AIA may further assist in the use of traditional
knowledge as prior art.
In hypothetically considering the neem-related patents as being
subject to the post-AIA patent rules, testimony regarding the hundreds of
years of public use of the neem tree as a pesticide, orally transmitted
information regarding its effectiveness, and foreign public use of the
neem tree would all be admissible to show that the American “invention”
lacks novelty or is obvious. 131
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Through the increasingly adversarial model of the USPTO’s
administrative system, the patent system as a whole has a tendency to
correct itself. As in the case of the Turmeric Patent, third parties may
participate in the administrative process and obtain cancellation of
invalid patents. 132 However, geographic limitations on prior art present a
substantial obstacle to the USPTO’s ability to perform that function.
Moreover, although the new Section 102 drastically expands the scope of
available prior art, the practical limitations of the USPTO and the
restrictions placed on the administrative system limit the impact these
changes will have on the issuance of new patents.
Federal regulations place limits on the availability of particular types
of documentation and when those documents may be presented by third
parties. Pre-issuance third party submissions are limited to patents,
published patent applications, or other printed publications. 133 Thus,
before the USPTO has issued a patent, third parties may only submit
evidence of public use if that use is contained in a printed publication.134
In a post-grant review, 135 third parties may offer evidence of prior public
use or sale. 136 However, a post-grant review may be sought only within
nine months of the issuance of the patent.137 Following that nine-month
period, a third party may initiate an inter partes review, 138 but only
patents and printed publications may be considered as prior art. 139 This
leaves a narrow nine-month window after the issuance of the patent in
which third parties may submit evidence of public use of the invention to
the USPTO.

132

See supra Part I.
35 U.S.C. § 122(e) (2012).
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Post-grant review is an administrative proceeding to determine the validity of a
recently granted patent.
136
See 35 U.S.C. § 321(b) (2012) (permitting third parties to “request to cancel as
unpatentable one or more claims of a patent on any ground that could be raised under
paragraph (2) or (3) or subsection 282(b) (relating to invalidity of the patent or any
claim)”) (emphasis added).
137
§ 321(c).
138
Inter partes review is an administrative proceeding through which a third party can
challenge the validity of one or more patent claims. It is available after the time period
for a post grant review has lapsed.
139
35 U.S.C. § 311(b) (2012) (“A petitioner in an inter partes review may request to
cancel as unpatentable 1 or more claims of a patent only on a ground that could be raised
under Section 102 or 103 and only on the basis of prior art consisting of patents or
printed publications”).
133

2015]

PHARMACEUTICALS AND BIOPIRACY

421

C. Federal Court Practice
Due to the short period in which a patent may be challenged at the
administrative level based on public use or sale, the courts are likely to
be the forum in which the AIA’s changes to Section 102 will invalidate
new patents. Courts will consider both oral and documentary evidence in
determining whether there has been a public use or sale of products
embodying the patent. For instance, in Trans-World Mfg. Corp v. Al
Nyman & Sons, Inc., the Federal Circuit upheld the sufficiency of
evidence supporting a jury verdict of obviousness based on both oral and
documentary evidence.140 The jury relied both on photographs of the
prior art and the testimony of one of the inventors himself. 141
While documentary evidence may be difficult to come by in cases
involving traditional medicine, oral evidence is still available. At trial,
cross-examination of inventors may reveal the obviousness or lack of
novelty of the claimed invention, as it did in Trans-World Mfg. Corp.
Additionally, those with personal knowledge of how the traditional
medicine was used may testify as to those facts. The fact that this type of
evidence is available at trial, but is largely unavailable at the
administrative level, means that the new Section 102 will have a greater
impact in patent litigation than in the issuance of new patents.
However, the trend toward accelerated litigation schedules for patent
cases may make the timely acquisition of such evidence difficult. In one
of the more aggressive district courts, the Western District of Tennessee,
invalidity and unenforceability contentions are due within ninety days
after an answer is filed. 142 In the Eastern District of Texas, a popular
forum for patent disputes, invalidity and unenforceability contentions are
due within thirty-five days of the initial case management conference.143
As of the drafting of this article, there has yet to be a patent
invalidated by prior art that only became applicable by the removal of the
geographic limitation from Section 102. Because the post-AIA version of
Section 102 applies to patents issued from applications having, at any
time, at least one claim with an effective filing date on or after March 16,
2013, there should soon be an increase in attention to the broader
availability of prior art.
Despite the challenges of putting evidence of foreign public use
before the USPTO and the difficulties faced in litigation, it is axiomatic
that a patent is essentially useless if it will be invalidated upon litigation.
140
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Therefore, pharmaceutical companies seeking patents relating to
traditional knowledge are likely to consider the scope of foreign public
knowledge, use, and sale in drafting their patent claims, even if that
information will never be presented to the USPTO.

VI.

CONCLUSION

After the passage of the America Invents Act, U.S. patent law
theoretically should refuse protection to a larger number of “inventions”
based on traditional knowledge. However, practical considerations
significantly limit the effect that the AIA will have on the patentability of
traditional knowledge. The American regulatory system is likely to
narrow the practical—as opposed to the statutory—scope of prior art.
Even if oral traditions in South Africa may qualify as prior art under the
statute, they will not have that effect at the administrative level unless the
patent examiner knows of those traditions. Additionally, as demonstrated
by pharmaceutical companies’ responses to traditional knowledge
databases, these companies are likely to move towards combining
remedies derived from traditional knowledge with more synthetic
elements, thus avoiding novelty and non-obviousness issues.
When the invention is known to the public before the issuance of a
patent, there is no need to encourage innovation or disclosure, so there is
no justification for the grant of patent protection. The America Invents
Act provides the beginnings of a solution both for this foundational
problem of U.S. patent law and for the injustice that can result from the
misappropriation of traditional knowledge. It cannot, however, solve this
problem entirely.
One solution would be to eliminate some of the evidentiary
restrictions in administrative procedures, thereby permitting witness
testimony regarding foreign public uses. That could be accomplished by
eliminating those restrictions in inter partes review or by extending the
time period for post-grant review, which contains fewer evidentiary
restrictions. However, this change would add to the USPTO’s already
considerable workload. It would also change the nature of the
proceedings such that they may become full adversarial trials bearing
closer resemblance to litigation in the federal courts than administrative
proceedings. Individual district courts could also decide to amend
litigation schedules through local patent rules in a way that would
provide defendants with more time to locate invalidating foreign prior
art. Both of these potential solutions would prolong an already lengthy
and expensive patent litigation process, which would not serve the
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parties, the courts, or the USPTO well. As is often the case, the law
cannot provide a perfect solution to this problem.
Due to practical and procedural constraints on the availability of
foreign prior art, the impact that the America Invents Act’s expansion of
the scope of prior art will have remains somewhat unclear. What is clear
is that the statute now permits traditional knowledge stakeholders to
introduce evidence of foreign public use in their efforts to invalidate
controversial patents. This possibility alone may be enough to deter
companies from drafting patent claims that cover traditional knowledge,
while allowing them to seek protection for their own innovations.

